Quantcast

Latest Auxilium Pharmaceuticals Inc. Stories

2014-08-28 08:27:24

Study Results of Concurrent CCH Injections to Treat Two Dupuytren's Contracture Cords with Delayed Finger Extension Selected for Best Paper Session; Data Support Safe and Effective Use of CCH for Treatment of Two Affected Joints Concurrently CHESTERBROOK, Pa., Aug. 28, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that data from trials evaluating the use of collagenase clostridium histolyticum (CCH) for treating two...

2014-08-27 08:27:00

CHESTERBROOK, Pa., Aug. 27, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Morgan Stanley Healthcare Conference to be held September 8-10, 2014 in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 10:55 a.m. ET on Wednesday,...

2014-08-21 20:22:34

LYNBROOK, N.Y., Aug. 21, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX(®) in the EU, today announced positive, statistically significant results from a randomized, double-blind Phase 2a study of CCH for the potential treatment of cellulite, or edematous fibrosclerotic panniculopathy. The results...

2014-08-21 08:28:27

Mid and High Level Doses Demonstrate Statistically Significant Improvement in Cellulite Across All Endpoints; Nearly 70% of Mid and High Dose Patients Satisfied or Very Satisfied with Results CHESTERBROOK, Pa., Aug. 21, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced positive results from a randomized, double-blind Phase 2a study of collagenase clostridium histolyticum (or CCH) for the treatment of edematous...

2014-08-11 16:27:52

LYNBROOK, N.Y., Aug. 11, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX(®) in the EU, today announced its financial results for the second quarter ended June 30, 2014 and provided a corporate update. "This was a momentous quarter of milestones for XIAFLEX both commercially and clinically. We saw...

2014-08-11 08:27:52

CHESTERBROOK, Pa., Aug. 11, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, announced that Andrew Saik will be appointed Chief Financial Officer, effective August 18, 2014. Mr. Saik will be responsible for all financial and information technology activities and relationships and will play a critical leadership role in executing Auxilium's diversification and growth strategy. "Andrew brings nearly 20 years...

2014-07-31 16:29:32

-Company to Host Conference Call That Day at 8:30 a.m. ET- CHESTERBROOK, Pa., July 31, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that the Company will release results for the second quarter of 2014 on Thursday, August 7, 2014 before the opening of the U.S. financial markets. The Company also will conduct a conference call that day at 8:30 a.m. ET to discuss results and highlights of the...

2014-07-31 08:34:32

Acceptance of Regulatory Submission Triggers $10 Million Milestone Payment to Auxilium CHESTERBROOK, Pa., July 31, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the Company will receive a $10 million regulatory milestone payment from its partner Asahi Kasei Pharma Corporation (Asahi Kasei). The payment is due because of the successful submission of a regulatory application to the Japanese Pharmaceutical...

2014-06-30 12:32:44

NEW YORK, June 30, 2014 /PRNewswire/ -- Levi & Korsinsky is investigating the Board of Directors of Auxilium Pharmaceuticals Inc. ("Auxilium" or "the Company") (NasdaqGS: AUXL) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to QLT Inc. (NasdaqGS: QLTI). http://photos.prnewswire.com/prnvar/20120409/MM84375LOGO Click here to learn more about the investigation: http://zlk.9nl.com/auxilium-pharmaceuticals-auxl, or...

2014-06-26 08:27:14

Accelerates Auxilium's Ongoing Transformation Into Leading North American Specialty Biopharmaceutical Company CHESTERBROOK, Pa. and VANCOUVER, Canada, June 26, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, and QLT Inc. (NASDAQ: QLTI) (TSX: QLT), a Canadian-based biotechnology company focused on developing innovative orphan ophthalmology products, today announced that they have entered into a definitive...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related